Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Kymera Therapeutics Q4 EPS $(0.25) Beats $(0.40) Estimate, Sales $47.88M Beat $41.96M Estimate

Author: Benzinga Newsdesk | February 22, 2024 08:03am
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.40) by 37.5 percent. This is a 58.33 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $47.88 million which beat the analyst consensus estimate of $41.96 million by 14.12 percent. This is a 196.70 percent increase over sales of $16.14 million the same period last year.

Posted In: KYMR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist